Novo Nordisk A/S (NYSE:NVO) Receives $76.00 Consensus Target Price from Analysts

Novo Nordisk A/S (NYSE:NVO) has earned an average rating of “Hold” from the twenty brokerages that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, ten have given a hold recommendation, six have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $59.20.

Several research firms have commented on NVO. UBS Group cut shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a report on Tuesday, August 5th. Rothschild & Co Redburn upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 16th. Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, September 9th. HSBC set a $70.00 price target on Novo Nordisk A/S in a report on Wednesday, October 1st. Finally, Hsbc Global Res upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 1st.

Novo Nordisk A/S Price Performance

NVO stock opened at $46.54 on Tuesday. The business’s 50-day moving average is $55.54 and its two-hundred day moving average is $61.58. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The firm has a market capitalization of $207.80 billion, a P/E ratio of 12.79, a P/E/G ratio of 2.33 and a beta of 0.65. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $112.52.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The business had revenue of $11.74 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Institutional Trading of Novo Nordisk A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NVO. Kingstone Capital Partners Texas LLC grew its position in shares of Novo Nordisk A/S by 301,443.6% in the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock valued at $690,560,000 after buying an additional 10,001,898 shares during the last quarter. Nuveen LLC acquired a new position in Novo Nordisk A/S in the first quarter valued at $370,272,000. SG Americas Securities LLC grew its holdings in shares of Novo Nordisk A/S by 2,101.5% during the third quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock worth $132,242,000 after purchasing an additional 2,274,925 shares during the last quarter. Amundi increased its position in shares of Novo Nordisk A/S by 49.1% during the first quarter. Amundi now owns 4,938,507 shares of the company’s stock worth $331,576,000 after purchasing an additional 1,627,051 shares in the last quarter. Finally, Bank of Montreal Can lifted its holdings in shares of Novo Nordisk A/S by 101.4% in the 2nd quarter. Bank of Montreal Can now owns 2,475,300 shares of the company’s stock valued at $170,845,000 after purchasing an additional 1,246,467 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.